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Abstract. 
 
Myoblasts, the precursors of skeletal muscle 
ﬁbers, can be induced to withdraw from the cell cycle 
and differentiate in vitro. Recent studies have also 
identiﬁed undifferentiated subpopulations that can self-
renew and generate myogenic cells (Barofﬁo, A., M. 
Hamann, L. Bernheim, M.-L. Bochaton-Pillat, G. Gab-
biani, and C.R. Bader. 1996. 
 
Differentiation.
 
 60:47–57; 
Yoshida, N., S. Yoshida, K. Koishi, K. Masuda, and Y. 
Nabeshima. 1998. 
 
J
 
.
 
 Cell Sci
 
. 111:769–779). Cultured 
myoblasts can also differentiate and contribute to re-
pair and new muscle formation in vivo, a capacity ex-
ploited in attempts to develop myoblast transplantation 
(MT) for genetic modiﬁcation of adult muscle. Our 
studies of the dynamics of MT demonstrate that cul-
tures of myoblasts contain distinct subpopulations de-
ﬁned by their behavior in vitro and divergent responses 
to grafting. By comparing a genomic and a semicon-
served marker, we have followed the fate of myoblasts 
transplanted into muscles of dystrophic mice, ﬁnding 
that the majority of the grafted cells quickly die and 
only a minority are responsible for new muscle forma-
tion. This minority is behaviorally distinct, slowly divid-
ing in tissue culture, but rapidly proliferative after 
grafting, suggesting a subpopulation with stem cell–like 
characteristics.
Key words: skeletal muscle • myoblast transplanta-
tion • cell heterogeneity • stem cells • mdx mouse
 
A
 
DULT
 
 skeletal muscle exhibits a remarkable capacity
for regeneration following damage, an ability which
resides in a population of precursor cells, termed
satellite cells, sequestered between the basement mem-
brane and sarcolemma of individual muscle fibers. Such
cells are normally quiescent, but following tissue damage,
become activated to migrate, proliferate, and differentiate,
thereby effecting repair and regeneration (reviewed in
Pastoret and Partridge, 1998). In certain respects, regener-
ation in the adult recapitulates the embryogenesis of skel-
etal muscle during which muscle precursor cells (MPCs)
 
1
 
migrate from the somitic mesoderm, proliferate, and fi-
nally differentiate to form muscle fibers (Buckingham,
1992). However, although the precise origins and lineage
of satellite cells are ill-defined, in vitro studies have dem-
onstrated clear differences between MPCs prepared from
prenatal and adult muscle (Cossu et al., 1992; Smith et al.,
1993). This distinction has also been suggested by in vivo
studies which show that myonuclei derived from MPCs in-
volved in muscle development and growth migrate from
the center to the periphery of the maturing muscle fiber,
whereas MPCs derived from satellite cells involved in
postnatal regeneration in mice give rise to permanently
centrally nucleated fibers (Grounds et al., 1980; Pastoret
and Sebille, 1995). The presence of two populations of
MPC has also been demonstrated in postnatal, growing rat
muscle, with a majority of rapidly dividing cells, available
for incorporation with little or no proliferation during
growth, and a slowly dividing, but potentially highly prolif-
erative reserve population involved in the generation of
the former population and self-renewal (Rantanen et al.,
1995; Schultz, 1996). Clonal analysis of satellite cells iso-
lated from growing and regenerating rat muscles further
suggests that these populations may continue to be distin-
guishable in vitro (Schultz and Jaryszak, 1985). Recent
studies have also revealed heterogeneity within myogenic
cultures derived from single cells (Baroffio et al., 1995,
1996; Yoshida et al., 1998), a minority of cells remaining
undifferentiated when cultured in conditions designed to
induce terminal differentiation, while retaining the ability
to proliferate and apparently self-renew.
 
Address correspondence to Dr. J.R. Beauchamp, Muscle Cell Biology
Group, MRC Clinical Sciences Centre, Imperial College School of
Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN,
United Kingdom. Tel.: 44-181-383-8266. Fax: 44-181-383-8264. E-mail:
jbeaucha@rpms.ac.uk
 
1. 
 
Abbreviations used in this paper: 
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-deoxyuridine; MT,
myoblast transplantation; MPCs, muscle precursor cells; TA, tibialis ante-
rior; TAg, SV-40 large T antigen. 
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The ability of myoblasts to incorporate into postnatal
skeletal muscle during regeneration is exploited by myo-
blast transplantation (MT; reviewed in Blau and Springer,
1995; Partridge and Davies, 1995), a potential therapeutic
approach to the treatment of primary inherited myopa-
thies (Partridge et al., 1989; Vilquin et al., 1996) and dis-
eases that could be ameliorated by the systemic delivery of
nonmuscle proteins from host muscle (Barr and Leiden,
1991; Dhawan et al., 1991; Yao et al., 1994; Hamamori et al.,
1995). MT involves delivery of exogenous myoblasts which
contribute to the formation of new muscle fibers during
repair and regeneration, and therefore result in genetic
modification of the host muscle. Thus far, the relevance of
myoblast heterogeneity to MT has not been explored, spe-
cifically, whether all MPCs are equivalent in terms of their
behavior following transplantation into regenerating adult
muscle.
We have followed the behavior of donor myoblasts dur-
ing the first few days after murine MT using a dual marker
system designed to measure the short-term persistence
and proliferation of donor cells (Beauchamp et al., 1997).
The system involves transplantation of male MPCs labeled
with radioactive thymidine into female mouse muscles,
thereby providing two donor cell markers, the Y chromo-
some and incorporated radiolabel, which can be measured
in the same muscle extract. These markers have different
modes of inheritance. Following division, each daughter
contains the same amount of Y chromosome and half of
the radiolabel present in the parent cell. The total number
of donor-derived nuclei in a host muscle can be deter-
mined from the amount of Y chromosome. The radiolabel,
by contrast, is passed semiconservatively to the progeny of
the originally labeled cell and is released from this popula-
tion only upon cell death. Thus, the total radioactivity
within the host muscle provides an estimate of the surviv-
ing proportion of the initial dose of donor DNA. Any in
vivo replication within the donor cell population will man-
ifest as a change in the ratio of the two markers, with a rel-
ative increase in the amount of Y chromosome.
Using this system, we show that even in an immunodefi-
cient, irradiated mdx host, an optimized environment for
MT (Morgan et al., 1990, 1993), all the donor-derived mus-
cle is produced from a minority of donor cells that survive
and proliferate rapidly in vivo under conditions in which
the majority of cells undergo rapid death. This minority is
also refractory to a period of culture in the presence of
concentrations of [
 
3
 
H]thymidine which are cytotoxic to
rapidly dividing cells, suggesting that myogenic cultures
contain a discrete subpopulation which divide slowly in
vitro, but are activated to undertake rapid and extensive
proliferation upon grafting into regenerating host muscle.
These cells may represent a permanent, distinct subpopu-
lation of stem cells capable of generating more rapidly di-
viding progeny and self-renewal, or may be comprised of
cells in transit through a specific part of the cell cycle at
the time of transplantation. Whatever their origin, these
cells are distinct in their ability to survive transplantation
(unlike the vast majority) and contribute to regeneration
in the postnatal host muscle. The presence of behaviorally
distinct populations of MPCs in mature muscle has impli-
cations for our understanding of growth, repair, and re-
generation in this tissue.
 
Materials and Methods
 
Cell Culture and Radiolabeling
 
H-2K
 
b
 
 clone 18, a cloned, conditionally immortal myogenic line, was de-
rived from a 4-wk-old male 
 
H-2K
 
b
 
-tsA58 heterozygote, carrying a single
copy of the thermolabile tsA58 mutant SV-40 large T antigen (TAg) un-
der the control of the 
 
H-2K
 
b
 
 promoter (Morgan et al., 1994). The line was
maintained at low density in DME (high glucose, with sodium pyruvate;
Life Technologies Inc.) supplemented with 20% FCS, 2% chick embryo
extract, 4 mM glutamine, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin
(Sigma Chemical Co.). Murine recombinant IFN-
 
g
 
 was added to the me-
dium (20 U/ml; Life Technologies Inc.) to increase transgene expression
through the 
 
H-2K
 
b
 
 promoter, and cultures were grown at 33
 
8
 
C in 10%
CO
 
2
 
, a temperature at which the thermolabile TAg protein is active.
Primary MPCs were prepared by enzymatic disaggregation of leg mus-
cles from 1-d-old male C57Bl/10 mice. Muscles were minced and digested
in HBSS (25 ml/mouse) containing 1 U/ml collagenase type III (Sigma
Chemical Co.) for 10 min at 37
 
8
 
C before repeated cycles of aspiration and
expulsion through the tip of a Pasteur pipette. Released cells were dis-
carded and fragments were subjected to two rounds of digestion in HBSS
containing 0.25% trypsin (Sigma Chemical Co.) as above. The trypsin was
inactivated by addition of an equal volume of HBSS containing 20% FCS,
and cells were collected by centrifugation at 350 
 
g
 
 for 10 min at 4
 
8
 
C. Cell
pellets were resuspended in growth medium consisting of DME (high glu-
cose, with sodium pyruvate) supplemented with 20% FCS, 2% chick em-
bryo extract, 4 mM glutamine, 100 U/ml penicillin, and 100 
 
m
 
g/ml strepto-
mycin. Undigested tissue fragments were removed by filtration through
45 
 
m
 
M-pore-diameter nylon mesh, and cells were plated and cultured at
37
 
8
 
C in 10% CO
 
2
 
.
MPCs were radiolabeled by culturing for 16 h in growth medium
containing 0.25 
 
m
 
Ci/ml [methyl-
 
3
 
H]thymidine (5 Ci/mmol) or [methyl-
 
14
 
C]
thymidine (54 mCi/mmol; Nycomed Amersham). Using this labeling
regime, 
 
.
 
95% of the radiolabel could be TCA-precipitated (data not
shown). To investigate the effects of radiolabeling on MPCs, [
 
14
 
C]thymi-
dine–labeled, [
 
3
 
H]thymidine–labeled, and unlabeled 
 
H-2K
 
b
 
 clone 18, MPCs
were plated at 500 cells/cm
 
2
 
. At each time point, cultures were examined
by phase-contrast microscopy and total cell number was calculated from
mean number of cells in 12 random fields of known area.
 
5-Bromo-2
 
9
 
-deoxyuridine (BrdU) Incorporation
 
H-2K
 
b
 
 clone 18 MPCs were plated at 500 cells/cm
 
2
 
,
 
 
 
cultured for 16 h in
growth medium containing 4 
 
m
 
M BrdU, and then immunostained with
mouse anti-BrdU antibody as described (Kaufman and Foster, 1988). In
brief, cultures were fixed at 
 
2
 
20
 
8
 
C in 95% ethanol, rinsed in PBS, and
then incubated for 30 min at room temperature in 2 M HCl. After three
20-min washes in 50 mM NaCl, 100 mM Tris-HCl, pH 7.4, the cells were
incubated for 1 h with mouse anti-BrdU antibody (diluted 1:20 in PBS),
for 30 min with a biotinylated rabbit polyclonal anti–mouse immunoglob-
ulins antibody (diluted 1:250 in PBS), and finally for 30 min with streptavi-
din-peroxidase (diluted 1:250). All antibodies were obtained from DAKO
Corp. Peroxidase activity was visualized with 3,3
 
9
 
-diaminobenzidine tet-
rahydrochloride and after counterstaining with hematoxylin, cultures
were examined by light microscopy. Percentages of BrdU-positive cells
were counted in six random fields, each containing 
 
$
 
200 cells.
 
Myoblast Transplantation
 
MPCs were detached from the culture vessel by incubation in 0.05%
trypsin/0.02% EDTA. An equal volume of growth medium was added to
inactivate the trypsin, and cells were collected by centrifugation at 350 
 
g
 
for 10 min at 4
 
8
 
C. Cell pellets were resuspended in HBSS such that 5
 
 3 
 
10
 
5
 
cells could be transplanted in a total volume of 5–10 
 
m
 
l. 3–4-wk-old female
mdx nude mice were anaesthetized, the skin overlaying the tibialis ante-
rior (TA) muscle was opened, and 5
 
 3 
 
10
 
5 
 
MPCs were injected into the
TA muscle using a Hamilton 7005 syringe. The needle was inserted longi-
tudinally into the muscle and withdrawn slowly as the plunger was de-
pressed to deliver the cells along the length of the muscle. Irradiated host
muscles had been exposed to 18 Gray of X-irradiation 3 d before trans-
plantation, a pretreatment previously shown to enhance MT in mice
(Morgan et al., 1990, 1993). 
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Measurement of Y Chromosome and Radiolabel in
Host Muscles
 
At the indicated time points, host muscles were removed, snap-frozen in
liquid nitrogen, and stored at 
 
2
 
80
 
8
 
C. Amounts of radiolabel and Y chro-
mosome were measured as described previously (Beauchamp et al., 1997).
In brief, muscles were thawed on ice, minced, and then digested to homo-
geneity for 16 h at 50
 
8
 
C in 50 mM Tris-HCl, 100 mM EDTA, 100 mM
NaCl, pH 8.0, containing 500 
 
m
 
g/ml proteinase K (Sigma Chemical Co.),
and 0.5% (wt/vol) SDS, with regular vortexing. To determine the amount
of radiolabel present, an aliquot was mixed with Hionic-Fluor liquid scin-
tillation counting fluid (Canberra Packard Ltd.) and the amount of iso-
tope measured using a Beckman LS6000SC counter system. DNA was ex-
tracted from the remaining digestion mixture and slot blotted onto
uncharged nylon membrane (Hybond-N; Nycomed Amersham), together
with appropriate control dilution series of male and female DNA. Before
slot blotting, the amount of isotope present in an aliquot of each DNA
preparation was measured as above to determine the efficiency of extrac-
tion. Slot blots were hybridized with a Y chromosome–specific DNA
probe, 145SC5 (Nishioka, 1988), and labeled with [
 
a
 
-
 
32
 
P]dCTP (Nycomed
Amersham) by random priming using Ready-To-Go DNA labeling beads
(Pharmacia Biotech Co). Hybridized membranes were exposed to a phos-
phor screen which was then scanned using a PhosphoImager 445 SI (Mo-
lecular Dynamics, Inc.). Quantitative analyses were carried out using Im-
ageQuant software (Molecular Dynamics, Inc.) and the amount of male
DNA present in each sample was determined by reference to a standard
curve obtained from control male DNA dilution series.
In the experiment presented in Fig. 2, host muscles were removed, solu-
bilized in Soluene
 
®
 
-350 (Canberra Packard Ltd.), and the amount of 
 
14
 
C
present was measured by scintillation counting after the addition of scin-
tillation counting fluid, as above.
 
Immunofluorescent Staining
 
8-
 
m
 
m-thick cryosections were cut and immunostained for dystrophin using
a sheep polyclonal antibody to the 60-kD dystrophin peptide (provided by
Professor E.P. Hoffman, University of Pittsburgh School of Medicine,
Pittsburgh, PA) as described (Partridge et al., 1989). In brief, unfixed sec-
tions were blocked in 5% horse serum in PBS, and then incubated for 1 h
with the primary antibody (1:1,000 dilution), for 1 h with an affinity-puri-
fied, biotinylated donkey antibody raised against sheep immunoglobulins
(diluted 1:400; Nycomed Amersham), and for 30 min with streptavidin–
Texas red (diluted 1:100; Nycomed Amersham). All dilutions were in 5%
horse serum in PBS. The slides were examined and photographed using a
Zeiss Axiophot fluorescence microscope.
 
Results
 
Most Transplanted MPCs Are Lost Rapidly from the 
Host Muscle
 
Initial studies were carried out using a cloned, condition-
ally immortal myogenic cell line, 
 
H-2K
 
b
 
 clone 18, derived
from a male mouse transgenic for the tsA58 mutant TAg
under the control of the inducible 
 
H-2K
 
b
 
 promoter (Mor-
gan et al., 1994). Donor MPCs were labeled with either
[
 
3
 
H]thymidine or [
 
14
 
C]thymidine, and then injected into
preirradiated TA muscles of 3–4-wk-old female nude mdx
mice, an optimized host environment for MT (Morgan et al.,
1990, 1993).
Identical results were obtained with [
 
3
 
H] and [
 
14
 
C]thy-
midine–labeled MPCs (Fig. 1). In the experiments shown,
each of which was carried out using a different prepa-
ration of 
 
H-2K
 
b
 
 clone 18 MPCs, there was a rapid loss of
80–95% of radiolabel and Y chromosome during the first
day after transplantation (at 24 h, mean percentage of
radiolabel remaining from all experiments 
 
5 
 
10.2 
 
6
 
 4.2;
mean percentage of male DNA remaining 
 
5 
 
11.2 
 
6
 
 1.6
[
 
6
 
 SEM,
 
 n 
 
5 
 
12]). During this period, the loss of the two
markers was concordant. The mean ratio of percentage of
radiolabel to percentage of male DNA present at 24 h re-
mained at 0.96 
 
6
 
 0.04 (
 
6
 
 SEM,
 
 n 
 
5 
 
12) compared with the
initial ratio of 1.0. Equivalent loss of Y chromosome dem-
onstrates that the disappearance of radiolabels was not
due to leakage of unincorporated thymidine. Further-
more, in some experiments, entire legs of host mice were
solubilized after removal of the injected TA muscles, and
were found to contain 
 
,
 
10% of the injected isotope 4 h af-
ter MT (data not shown). This, together with the finding
that MPCs incorporated within a fibrin clot are lost to the
same extent as when delivered in suspension (Beauchamp
et al., 1997), demonstrates that the disappearance of donor
cells is not simply due to leakage from the injection site
into surrounding compartments.
 
Rapid Cell Death Following MT Is Biphasic
 
The rapid disappearance of donor MPCs from host mus-
cles was confirmed and further defined by a detailed inves-
tigation of the first 24 h after MT (Fig. 2). Muscles har-
vested immediately after injection contained 85% of the
amount of label present in the transplanted cell popula-
tion, confirming that most of the cells were successfully de-
posited within the muscle. However, only 30% of the in-
jected label (
 
z
 
35% present immediately after injection)
remained after 1 h. Following the initial fall, amounts of
radiolabel present in muscles taken between 1 and 8 h af-
ter injection were relatively constant, at 
 
z
 
25% of that
transplanted. However, a second loss of label was ob-
served beginning 8–12 h after transplantation, suggesting a
biphasic loss of donor MPCs following MT: 
 
a
 
 rapid loss of
 
z
 
75% of the injected cell population, followed by a sec-
ond event beginning 8–12 h later, result in the loss of most
of the remaining cells, such that only 
 
z
 
1% of the injected
radiolabel remained 4 d after grafting (Fig. 1).
 
Surviving Transplanted MPCs Proliferate in the
Host Muscle
 
After the dramatic disappearance of donor cells during the
initial 24 h after injection, there was a progressive loss of
radiolabel such that 
 
z
 
1% of the injected radiolabeled-thy-
midine remained 4 d after transplantation (mean percent-
age of radiolabel remaining after 4 d 
 
5 
 
1.1 
 
6
 
 0.1 [
 
6
 
 SEM,
 
n 
 
5 
 
12]; Fig. 1 A). This value may actually overestimate
the persistence of the transplanted MPCs as some label
may have been released by dying cells and reused by host
cells. However, continued disappearance of donor cells
was accompanied by division of the remaining cells, as re-
vealed by a marked divergence of the labels. Thus, al-
though only 1% of the injected radiolabel persisted, the
mean percentage of Y chromosome present after 4 d from
all experiments was equivalent to 23.5% of the initial pop-
ulation (SEM 
 
6
 
 3.8,
 
 n 
 
5 
 
12). It is notable that, although
the percentages of Y chromosome present in individual
muscles after 4 d varied from 8 to 43%, the ranges within
each experiment were small (experiment 1, 8–11%; 2, 36–
43%; 3, 16–29%; Fig. 1
 
 
 
A), demonstrating that within an
equivalent group of host mice, each particular cell prep-
aration gave rise to equal numbers of donor cells irre-
spective of the radiolabel used. Furthermore, when Y
chromosome was measured in muscles transplanted with 
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unlabeled MPCs, the same results were obtained as with
equivalent labeled MPCs (Fig. 1 B, column b).
Extensive proliferation of the surviving fraction of do-
nor cells and their subsequent contribution to the forma-
tion or repair of muscle fibers was also evident from the
large numbers of dystrophin-positive profiles present in
muscles taken 3 wk after MT (Fig. 3). Again, no differ-
ences in the numbers or distributions of dystrophin-posi-
tive fibers were observed between muscles that had re-
ceived [
 
3
 
H]thymidine–labeled, [
 
14
 
C]thymidine–labeled, or
unlabeled MPCs. Together, these results demonstrate what
would appear to be a catastrophic loss of donor cells in the
immediate aftermath of MT, cited as an explanation for
failure of this technique (Huard et al., 1994; Fan et al.,
1996; Guérette et al., 1997), is in fact a standard feature of
successful transplantations, as in the above experiments,
and that success is due to extensive proliferation of a small
proportion of the cells rather than survival of the majority
of the transplanted population.
 
MPCs That Contribute to Muscle Formation In Vivo 
Divide Slowly In Vitro
 
It was surprising that identical results were obtained in
vivo with MPCs labeled with [
 
3
 
H]thymidine and [
 
14
 
C]thy-
midine (Fig. 1). In vitro, [
 
3
 
H]thymidine was cytotoxic for
the majority of the population, whereas [
 
14
 
C]thymidine
had no significant effect on survival or proliferation (Fig.
4). Previous studies, published 
 
.
 
30 yr ago, reported that
[
 
3
 
H]thymidine of high specific activity, such as used in the
present studies, was cytotoxic to HeLa cells, and only cells
which had not entered S phase during the period of label-
ing (and therefore remained unlabeled) retained the po-
tential to form colonies (Drew and Painter, 1962). Since
intranuclear [
 
3
 
H]thymidine is cytotoxic to MPCs in vitro,
this suggests that cells that survive MT and proliferate
within the host muscle environment had not undergone
DNA synthesis during the 16 h of radiolabeling, and may
therefore represent a subpopulation of MPCs defined by a
relatively slow generation time in vitro. When 
 
H-2K
 
b
 
clone 18 MPCs were cultured under the same conditions
used for radiolabeling, but in the presence of BrdU, immu-
nostaining for BrdU incorporation revealed that 3 
 
6
 
 0.3%
(
 
6
 
 SEM,
 
 n 
 
5 
 
8) of the population had not entered S phase
during that time, suggesting an upper limit to size of the
subpopulation responsible for muscle formation in vivo.
 
had been transplanted with [
 
14
 
C]thymidine–labeled MPCs
(right). Each pair of columns represents percentages of radiola-
bel and Y chromosome remaining in an individual muscle. (B)
Representative slot blot of DNA extracted from irradiated fe-
male nude mdx mouse muscles injected with unlabeled or radio-
labeled male MPCs, probed for Y chromosome. (a) Series of con-
trol samples prepared from noninjected female muscles
combined with 7.5–0.5
 
 3 
 
10
 
5
 
 male MPCs; (b) DNA extracted
from muscles injected with 5
 
 3 
 
10
 
5
 
 unlabeled cells; (c and d)
DNA extracted from muscles injected with the same number of
[
 
3
 
H]thymidine–labeled MPCs; and (e and f) DNA from muscles
injected with [
 
14
 
C]thymidine–labeled cells. The time at which
each muscle was harvested after MT is shown at the right of the
figure. The top slots in b, c, and e contain DNA extracted from
representative cell pellets containing 5
 
 3 
 
10
 
5
 
 unlabeled or la-
beled MPCs. The signal from each slot was measured using a
PhosphoImager and values obtained from a were used to con-
struct a linear standard curve of signal against number of donor
cells (data not shown). Signals obtained from injected muscles
were within the linear range of this system, which is maintained
with as little as 1 ng of target DNA (equivalent to 
 
z
 
200 genome
copies; Beauchamp et al., 1997). Values obtained from this blot
are presented in A, experiment 1.
 
Figure 1
 
. Loss and proliferation of MPCs following myoblast
transplantation into irradiated host muscle. (A) Irradiated left
TA muscles of female nude mdx mice were transplanted with 5
 
 3
 
10
 
5 
 
radiolabeled male 
 
H-2K
 
b 
 
clone 18 MPCs. At the times indi-
cated, mice were killed and amounts of Y chromosome (filled
columns) and radiolabel (open columns) were measured and are
presented as percentages. In each experiment, most donor MPCs
disappeared from host muscles during the initial 24 h after MT, as
shown by a coincident loss of the majority of donor cell markers.
During the subsequent 3 d, amounts of Y chromosome revealed
marked proliferation of surviving cells, despite the continued,
progressive disappearance of the radiolabeled population. In
each experiment shown, four mice were killed at each time point,
two had received [
 
3
 
H]thymidine–labeled MPCs (left), and two 
Beauchamp et al. 
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Preirradiation of the Host Muscle Enhances Donor 
MPC Proliferation, but Not Survival
The preceding data are from experiments in which MPCs
were injected into preirradiated host muscles, a treatment
previously shown to increase the efficacy of MT (Morgan
et al., 1990, 1993). To investigate the effects of preirradia-
tion of host muscles on the short-term behavior of trans-
planted MPCs, the right legs of a series of female nude
mdx mice were irradiated before bilateral MT with radio-
labeled primary cells derived from male neonatal muscle.
In the irradiated muscles and the contralateral, nonirradi-
ated controls, there was a similar loss, both in timing and
extent, of virtually all the transplanted radiolabel over the
experimental period (Fig. 5). As with the conditionally im-
mortal cell line, the amount of Y chromosome showed a
progressive relative increase from 24 h after MT onwards
compared with the amount of radiolabel, in both the irra-
diated and control muscles. However, the amount of Y
chromosome increased to a greater extent in the irradiated
muscles, suggesting that there was greater proliferation of
surviving MPCs than in nonirradiated muscles. Thus, the
increased efficacy of MT in preirradiated host muscles is
not the result of increased cell survival, but may be attrib-
uted to increased proliferation of the surviving subpopula-
tion. Furthermore, data presented in Fig. 5 also show that
successful MT through the rapid expansion of a small
number of surviving MPCs is not peculiar to conditionally
immortal myogenic lines. In fact, when injected into irradi-
ated host muscles, more donor-derived nuclei were gener-
ated from primary cells than from the same numbers of
cloned, conditionally immortal MPCs, although a similarly
large proportion of cells was lost in the immediate after-
math of transplantation.
Discussion
Successful genetic modification of skeletal muscle by MT
requires the survival of donor myoblast nuclei and their
stable incorporation into muscle fibers within the host tis-
sue. Attempts to develop MT into a viable approach to
gene therapy have focused on modification of the host tis-
sue and control of inflammatory and immunological re-
sponses to the graft (Tremblay and Guerette, 1997). In
contrast, scant attention has been paid to donor cells until
recently (Gussoni et al., 1997; Qu et al., 1998). In the con-
text of MT, the term myoblast is simply used to describe a
mononucleated, undifferentiated cell with the potential to
initiate the myogenic program, withdraw from the cell cy-
cle, and differentiate to form skeletal muscle. However,
our studies of early events following MT reveal markedly
divergent behavior within myoblast populations, even in
X-irradiated muscles of nude mdx mice, a highly permis-
sive environment for MT (Morgan et al., 1990, 1993). The
vast majority of donor MPCs die in the aftermath of MT,
and muscle of donor-origin is derived from only a tiny pro-
portion of the injected population which undergo rapid
and extensive proliferation in vivo. This phenomenon was
Figure 3. Dystrophin expression in sections of irradiated mdx
muscles, 3 wk after transplantation of unlabeled or radiolabeled
normal MPCs. Cryosections of irradiated, nude mdx TA muscles
were immunostained for the presence of dystrophin 3 wk after
transplantation of 5 3 105 H-2Kb clone 18 MPCs. No differences
in numbers or distribution of dystrophin-positive fibers were ob-
served between muscles injected with [3H]thymidine–labeled (a),
[14C]thymidine–labeled (b), or unlabeled (c) donor cells. A con-
trol muscle injected with 5 ml of medium is shown, containing a
single dystrophin-positive revertant fiber (d).
Figure 2. Biphasic loss of donor MPCs from irradiated host mus-
cles during the initial 24 h after transplantation. [14C]Thymidine–
labeled H-2Kb clone 18 MPCs were injected into irradiated left
TA muscles of nude mdx mice. Each muscle received 5 3 105
cells and at the times indicated, amount of 14C present in host
muscles was measured. Less than 10% of the injected radiolabel
remained 24 h after MT. 60% was lost during the first 60 min and
a second event, initiated $8 h after MT, resulted in the subse-
quent disappearance of most of the remaining label. Results are
presented as percentages of 14C present in 5 3 105 labeled MPCs,
and each time point is the mean value from four muscles 6 1 SD.
Muscles taken at 0 h were removed as quickly as possible after
MT (i.e., ,5 min) and contained z85% of the injected label.The Journal of Cell Biology, Volume 144, 1999 1118
observed with both primary MPCs and a myogenic cell
line derived from the H-2Kb-tsA58 transgenic mouse, sug-
gesting that expression of TAg maintains the population
capable of repopulating muscle in vivo.
To follow the fate of donor myoblasts during the first
few days after transplantation into dystrophic host muscle,
we have developed a method based upon quantitative
comparisons between a genetic marker (Y chromosome)
and a semiconserved label (radiolabeled thymidine) of do-
nor DNA (Beauchamp et al., 1997). Since both labels are
measured directly, this combination has an advantage over
other commonly used reporter systems such as b-galac-
tosidase and green fluorescent protein, the use of which
may be confounded by variation in the level of gene ex-
pression or accumulation of product, particularly when la-
beled cells may be at different stages of differentiation.
Loss of either label will occur only on cell death (loss of ra-
diolabeled thymidine due to DNA repair would be trivial
in the time course of this experiment). Thus, in our system,
the amount of Y chromosome provides an absolute mea-
sure of the number of copies of donor cell–derived ge-
nome, while the amount of radiolabel directly reflects the
proportion of originally grafted donor cell DNA which has
survived in the recipient muscle. Our intention to use the
change in ratio between the genetic and semiconserved la-
bels to assess cell proliferation is predicated on uptake of
radiolabeled thymidine by a single homogeneous popula-
tion. However, the almost complete loss of radiolabel in
conjunction with increasing amounts of Y chromosome re-
vealed that labeling was not homogenous and suggested
the presence of two donor cell populations of diverse be-
havior. One, proliferative in culture and therefore readily
poisoned by [3H]thymidine, is sensitive to transplantation
into muscles. The second, a minor subpopulation, slowly
dividing in culture and thus refractory to [3H]thymidine,
survives transplantation and proliferates rapidly in vivo.
This unexpectedly clear-cut distinction, to some extent, vi-
tiates the use of the ratio of labels as a quantitative mea-
sure of cell proliferation. Thus, with progressive decline of
radiolabel towards background levels, the best indicator of
the behavior of the surviving subpopulation is the change
in the absolute measures of Y chromosome content which,
for example, illustrates a clear difference between the
rapid proliferation of cells in preirradiated muscles and
slower rates in nonirradiated muscles.
Our findings raise two fundamental questions. Why
should a consistently small, but highly prolific, subpopula-
tion of donor MPCs survive the apparent rigors of MT,
and what causes the death of the vast majority of trans-
planted MPCs?
The identity of cells which proliferate and contribute to
muscle formation is crucial to the first of these questions.
Our data suggest that the surviving cells constitute a dis-
tinct minority which, for unknown reason(s), are resistant
to the early events after MT, and are not merely chance
survivors of a purely stochastic process of cell death. We
observed the same dynamics of rapid cell death and even-
tual outcome of MT in terms of new muscle formation
with unlabeled, [14C]thymidine–labeled, or [3H]thymi-
Figure 5. Comparative behavior of primary MPCs in irradiated
and nonirradiated host muscles. TA muscles of female nude mdx
mice were injected with 5 3 105 [3H]thymidine–labeled male pri-
mary MPCs. The right legs of host mice had been irradiated 3 d
before transplantation. Amounts of Y chromosome (filled col-
umns) and 3H (open columns) were measured in muscles of host
mice killed at times indicated after MT. In both irradiated and
contralateral, nonirradiated muscles, there was similar progres-
sive loss of radiolabel over 4 d. However, after an initial fall at 4 h
equal to that of radiolabel, amounts of Y chromosome increased
in both series, although increase in irradiated muscles was consid-
erably greater than in nonirradiated, contralateral muscles. Each
column is the mean of two muscles, presented as percentages of
marker injected, determined by analysis of cell pellets prepared
as for transplantation.
Figure 4. Differential effects of labeling with [14C]thymidine and
[3H]thymidine on MPCs in vitro. H-2Kb clone 18 MPCs were cul-
tured for 16 h in the presence of 0.25 mCi/ml of either [14C]thymi-
dine or [3H]thymidine, and then replated at 500 cells/cm2. The
numbers of cells in cultures of [14C]thymidine–labeled (filled cir-
cles), [3H]thymidine–labeled (filled squares), and control unla-
beled (open circles) cells were counted over 4 d. Each point is the
mean of three cultures 6 1 SD. The growth of MPCs precultured
in presence of equivalent concentrations of unlabeled thymidine
(4.6 mM for [14C]thymidine and 50 pM for [3H]thymidine) was in-
distinguishable from the control, unlabeled cells at thymidine
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dine–labeled MPCs, despite the fact that the latter label is
cytotoxic to dividing cells. Cells which proliferate after
transplantation and give rise to the donor muscle there-
fore must have been those that are refractory to [3H]label-
ing, presumably because they had not passed through S
phase during the 16-h period of in vitro labeling. That the
loss of injected MPCs was identical irrespective of labeling
suggests that cells in rapid cycle in vitro (which are readily
labeled) are those which die following MT, and are irrele-
vant to the final outcome. Further, this demise is an innate
feature of this category of cell since its occurrence is unaf-
fected by the toxicity of the label. In contrast, the cells
which do not incorporate radiolabel in vitro further dem-
onstrate their inherent behavioral individuality by under-
taking rapid proliferation soon after transplantation into
irradiated muscle, in conditions which the previously pro-
liferative majority are dying. These findings parallel those
in heterogeneous populations of hematopoietic cells, where
exposure to high specific activity [3H]thymidine has been
shown to selectively kill cycling cells while preserving
long-term culture-initiating cells (Ponchio et al., 1995), and
argue in favor of the idea that cells which give rise to mus-
cle on transplantation into muscle constitute a distinct sub-
population, apparently with some stem cell–like properties.
The existence of a stem cell–like subpopulation of MPC
has also been suggested by recent studies of myoblasts in
tissue culture. Yoshida et al. (1998) identified a population
of reserve cells in the myogenic cell line, C2, which, when
exposed to differentiation conditions, persisted as slowly
cycling, undifferentiated, mononuclear cells with the ca-
pacity to self-renew and give rise to differentiating cells.
Phenotypically distinct, nonfusing cells that can divide
asymmetrically to self-renew and generate committed cells
have also been identified within individual clones of hu-
man MPCs (Baroffio et al., 1996). These presumptive stem
cells comprised z2% of each clone (very similar to our
3% upper limit of murine muscle-forming MPCs which did
not enter S phase during labeling) and decreased in num-
ber with successive passages, which may account for the
finding that culture of avian myoblasts results in a progres-
sive decrease in the amount of muscle formed following
transplantation (DiMario and Stockdale, 1995). Recently,
Dominov et al. (1998) reported that Bcl-2, an apoptosis-
inhibiting protein, is expressed by myoblasts at an early
stage of differentiation and may promote clonal expansion
of myogenic cells. Intriguingly, only 1–4% of cells in pri-
mary myogenic cultures were found to be positive for Bcl-2
(Dominov et al., 1998). It is possible that the subpopula-
tion with some stem cell–like properties, previously identi-
fied in vitro (Baroffio et al., 1995, 1996; Dominov et al.,
1998; Yoshida et al., 1998), may correspond to those we
define by their behavior in vivo, i.e., relative robustness
when transplanted.
Why most donor MPCs die following MT remains un-
clear. Our results show that z99% of radiolabeled donor
cells had died and were cleared from the host muscles 4 d
after grafting. The remaining 1% defines an upper limit to
the survival of radiolabeled cells, as some reutilization of
label released from dead donor MPCs may have occurred,
although the extent of any reutilization was clearly insig-
nificant compared with the total amount of label trans-
planted. We found no evidence of donor cell apoptosis
during the first 6 h after MT when sections of host muscle
were analyzed by terminal deoxynucleotidyl transferase–
mediated deoxyuridine triphosphate endlabeling, a tech-
nique which reveals DNA strand breaks characteristic of
apoptotic nuclei (data not shown). The mechanism is also
unlikely to be a specific immunological response to donor
MPCs as death occurs within 2–3 d following either trans-
plantation into isogenic (Huard et al., 1994), congenic
(Fan et al., 1996), immunodeficient, or immunosuppressed
hosts (Beauchamp, J.R., J.E. Mogan, C.N. Pagel, and T.A.
Partridge. 1994. Muscle Nerve. 18:S261; Guérette et al.,
1997). A recent study has implicated a nonspecific inflam-
matory reaction, possibly initiated in response to tissue
damage, which may be inhibited by antibody-mediated
blockade of leukocyte function associated molecule-1 (Gué-
rette et al., 1997). Our analysis of the first 24 h after MT
suggests that the rapid loss of cells may involve two events,
the second of which, beginning 8–12 h after injection, may
indeed be attributable to such an inflammatory reaction.
However, this is unlikely to account for the initial loss of
#70% of donor cells within 1 h of transplantation. Rather,
this rapid necrotic demise of the most proliferative portion
of the population of grafted MPCs suggests the cells are
maladapted to some aspect of the environment within the
recipient muscle, perhaps anoxia, although the rapid re-
moval of released radiolabel from the graft site seems
to imply that it is efficiently perfused. In the study of
Guérette et al. (1997), the percentage of donor cells sur-
viving 3 d after grafting was calculated relative to that
measured 1 h after MT. Our results show that significant
cell death occurs during the first hour after grafting, so the
initial phase of cell death following grafting would have
been missed. However, recent findings of Qu et al. (1998)
also imply a biphasic loss of donor MPCs following MT.
When either an mdx cell line or myoblasts isolated from
isolated muscle fibers were grafted, substantial losses of
donor cells were measured 12 h after injection. In marked
contrast, primary myogenic cells selected by a sequential
preplating regime survived transplantation, apparently
without loss. However, although the selected primary cells
persisted for 48 h, there were marked losses during the
subsequent 3 d. Furthermore, when the mdx cell line was
engineered to produce IL-1 receptor antagonist protein in-
tended to block any early inflammatory reaction, the ini-
tial loss of donor cells was largely unaffected, although the
subsequent disappearance observed 2–5 d after transplan-
tation was prevented (Qu et al., 1998). These results sup-
port the idea that loss of donor MPCs following MT in-
volves two events, the first as yet undefined and to which
different preparations of donor MPC may be differentially
susceptible, followed by a second, inflammation-mediated
event.
The identification of a relatively undifferentiated sub-
population, slowly dividing (and probably selected against)
in culture, but driven into rapid proliferation upon being
grafted into preirradiated muscle, and in consequence re-
sponsible and therefore required for successful MT in
vivo, has significant implications for human MT. Failure to
reproduce the promising results obtained with mdx mice
in clinical trials of MT on boys with Duchenne muscular
dystrophy has been variously attributed to lack of host
muscle regeneration, the presence of significant connec-The Journal of Cell Biology, Volume 144, 1999 1120
tive tissue barriers (both consequences of recipient age),
and immune rejection (Gussoni et al., 1992; Karpati et al.,
1993; Roy et al., 1993; Tremblay et al., 1993a,b; Mendell et
al., 1995; Morandi et al., 1995; Miller et al., 1997). The abil-
ity of human MPCs to survive transplantation was also
questioned (Gussoni et al., 1992; Karpati et al., 1993) and
subsequent reports of rapid donor cell death during the af-
termath of MT in mice (Beauchamp, J.R., J.E. Mogan,
C.N. Pagel, and T.A. Partridge. 1994. Muscle Nerve. 18:
S261; Huard et al., 1994; Fan et al., 1996; Guérette et al.,
1997) have suggested that this may have contributed to the
failure of clinical trials. Our results also demonstrate that
the vast majority of transplanted MPCs die within hours of
delivery. However, we have shown that this phenomenon
does not lead to inevitable failure, as it occurs during suc-
cessful MT. Recent reevaluation of biopsies of recipient
muscles from an earlier clinical trial of human MT on boys
with Duchenne muscular dystrophy (Gussoni et al., 1992)
revealed the persistence of unexpectedly large numbers of
donor-derived nuclei, many of which had become incorpo-
rated into mature myofibers, but did not express dystro-
phin (Gussoni et al., 1997). Therefore, at least in human
MT, the ability of donor cells to survive grafting does not
inevitably lead to biochemical modification of host tissue,
possibly due to environmental influences encountered in
diseased, dystrophic muscle. Nevertheless, the ability to
isolate and maintain a population of human MPCs equiva-
lent to those responsible for successful MT in mice could
greatly enhance the therapeutic potential of a given dose
of donor cells, and might obviate the extensive cloning
and expansion in vitro (Law et al., 1993; Tremblay et al.,
1993a,b; Mendell et al., 1995), or selection on the basis of
neural cell adhesion molecule expression (Gussoni et al.,
1992; Karpati et al., 1993; Morandi et al., 1995; Miller et
al., 1997), which may have helped to confound the poten-
tial success of MT in human trials. Considerable interest in
the possible use of stem cells for genetic conversion of
adult skeletal muscle has resulted from the demonstration
that bone marrow–derived cells can contribute to skeletal
muscle regeneration, following either direct grafting into
host muscle or bone marrow transplantation (Ferrari et
al., 1998). Whether derived from bone marrow or isolated
from heterogeneous myogenic cultures (Baroffio et al.,
1995, 1996; Dominov et al., 1998; Yoshida et al., 1998),
precursor cells with the potential to contribute to new
muscle formation, particularly after the initial transplanta-
tion, would be invaluable for the development of MT.
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